1. Home
  2. SPRO vs MCRB Comparison

SPRO vs MCRB Comparison

Compare SPRO & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRO
  • MCRB
  • Stock Information
  • Founded
  • SPRO 2013
  • MCRB 2010
  • Country
  • SPRO United States
  • MCRB United States
  • Employees
  • SPRO N/A
  • MCRB N/A
  • Industry
  • SPRO Biotechnology: Pharmaceutical Preparations
  • MCRB Biotechnology: Pharmaceutical Preparations
  • Sector
  • SPRO Health Care
  • MCRB Health Care
  • Exchange
  • SPRO Nasdaq
  • MCRB Nasdaq
  • Market Cap
  • SPRO 107.5M
  • MCRB 125.7M
  • IPO Year
  • SPRO 2017
  • MCRB 2015
  • Fundamental
  • Price
  • SPRO $1.87
  • MCRB $19.44
  • Analyst Decision
  • SPRO Buy
  • MCRB Hold
  • Analyst Count
  • SPRO 4
  • MCRB 4
  • Target Price
  • SPRO $5.00
  • MCRB $73.67
  • AVG Volume (30 Days)
  • SPRO 798.2K
  • MCRB 126.4K
  • Earning Date
  • SPRO 08-12-2025
  • MCRB 08-06-2025
  • Dividend Yield
  • SPRO N/A
  • MCRB N/A
  • EPS Growth
  • SPRO N/A
  • MCRB N/A
  • EPS
  • SPRO N/A
  • MCRB 10.22
  • Revenue
  • SPRO $48,576,000.00
  • MCRB N/A
  • Revenue This Year
  • SPRO N/A
  • MCRB N/A
  • Revenue Next Year
  • SPRO N/A
  • MCRB N/A
  • P/E Ratio
  • SPRO N/A
  • MCRB $1.98
  • Revenue Growth
  • SPRO N/A
  • MCRB N/A
  • 52 Week Low
  • SPRO $0.51
  • MCRB $6.53
  • 52 Week High
  • SPRO $3.22
  • MCRB $26.40
  • Technical
  • Relative Strength Index (RSI)
  • SPRO 35.23
  • MCRB 69.44
  • Support Level
  • SPRO $1.80
  • MCRB $15.79
  • Resistance Level
  • SPRO $2.38
  • MCRB $18.12
  • Average True Range (ATR)
  • SPRO 0.12
  • MCRB 1.51
  • MACD
  • SPRO -0.02
  • MCRB 0.28
  • Stochastic Oscillator
  • SPRO 12.07
  • MCRB 97.69

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About MCRB Seres Therapeutics Inc.

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Share on Social Networks: